International Journal of Hematology

, Volume 106, Issue 4, pp 484–489 | Cite as

Prevalence and clinical outcomes of hepatitis B virus infection in patients with aplastic anemia

Original Article

Abstract

The association of HBV infection with other hematopoietic diseases has been discussed previously. However, the clinical significance and clinical outcomes of HBV infection in AA patients have not been clarified. In this study, we sought to investigate the prevalence and related events of HBV in patients with AA who received immunosuppressive therapy. We retrospectively analyzed 245 patients with acquired AA. The HBsAg positivity rate was 14.69% in this group of AA patients. No significant difference was observed in the severity of AA patients with HBV infection and in those without (P = 0.6358). HBV reactivation occurred in 4.76% of HBsAg-positive patients who received ATG/ALG + CsA treatment without anti-viral prophylaxis. HBV-infected patients who received CsA alone did not develop reactivation. Patients with HBV reactivation showed favorable clinical outcomes, with no HBV-related deaths. There was no significant difference in overall probability of survival in patients with different HBV infection status (P = 0.8617). Given the low rate of reactivation and favorable outcomes after reactivation in AA patients, close monitoring of HBV DNA, hepatic function and patient immune status may be a more effective approach than routine prophylaxis for AA patients with HBV infection undergoing ATG/ALG + CsA treatment. Further studies are warranted to clarify the optimal time to initiate anti-viral treatment.

Keywords

Hepatitis B virus Aplastic anemia Reactivation Hepatitis Immunosuppressive therapy 

References

  1. 1.
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–44.CrossRefPubMedGoogle Scholar
  2. 2.
    Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–92.CrossRefPubMedGoogle Scholar
  3. 3.
    Chen MH, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Teng HW, et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma. Ann Hematol. 2008;87:475–80.CrossRefPubMedGoogle Scholar
  4. 4.
    Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11:827–34.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Huang B, Li J, Zhou Z, Zheng D, Liu J, Chen M. High prevalence of hepatitis B virus infection in multiple myeloma. Leuk Lymphoma. 2012;53:270–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Rauff B, Idrees M, Shah SA, Butt S, Butt AM, Ali L, et al. Hepatitis associated aplastic anemia: a review. Virol J. 2011;8:87.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120:1185–96.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    International Agranulocytosis and Aplastic Anemia Study. Incidence of aplastic anemia: the relevance of diagnostic criteria. Blood. 1987;70:1718–21.Google Scholar
  9. 9.
    Guinan EC. Diagnosis and management of aplastic anemia. Hematol Am Soc Hematol Educ Program. 2011;2011:76–81.Google Scholar
  10. 10.
    Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31:1169–75.CrossRefPubMedGoogle Scholar
  11. 11.
    Marsh JCW, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Hematol. 2009;147:43–70.CrossRefGoogle Scholar
  12. 12.
    Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Reprint of: epidemiological serosurvey of Hepatitis B in China—declining HBV prevalence due to Hepatitis B vaccination. Vaccine. 2013;31(Suppl 9):J21–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Smith PR, Zampino R, Gutteridge C, Karayiannis P, Aitken C. Reactivation of precore variant hepatitis B virus in a child with severe aplastic anaemia. J Med Virol. 2001;65:470–2.CrossRefPubMedGoogle Scholar
  14. 14.
    Dai MS, Kao WY, Shyu RY, Chao TY. Restoration of immunity and reactivation of hepatitis B virus after immunosuppressive therapy in a patient with severe aplastic anaemia. J Viral Hepat. 2004;11:283–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2:152–62.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Xie HY, Xia WL, Zhang CC, Wu LM, Ji HF, Cheng Y, et al. Evaluation of hepatitis B virus replication and proteomic analysis of HepG2.2.15 cell line after cyclosporine A treatment. Acta Pharmacol Sin. 2007;28:975–84.CrossRefPubMedGoogle Scholar
  17. 17.
    Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood. 2007;109:3219–24.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Chen J, Wang J, Yang J, Zhang W, Song X, Chen L. Concurrent infection of hepatitis B virus negatively affects the clinical outcome and prognosis of patients with non-Hodgkin’s lymphoma after chemotherapy. PLoS One. 2013;8:e69400.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.CrossRefPubMedGoogle Scholar
  20. 20.
    EASL Clinical Practice Guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.CrossRefGoogle Scholar
  21. 21.
    Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–61.CrossRefPubMedGoogle Scholar
  22. 22.
    Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011;90:1219–23.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  1. 1.Department of HematologyAffiliated Hospital of North Sichuan Medical CollegeNanchongChina
  2. 2.Department of HematologyNanchong Central HospitalNanchongChina
  3. 3.Chengdu Gaoxin Boli HospitalChengduChina

Personalised recommendations